Revolution Medicines, Inc. (RVMD): Cash & Equivalents
$383.75M
As of 2025-12-31
$815.43M
As of 2026-06-30
+33.5%
3-year compound annual growth
+29.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $383.75M | -29.3% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $543.06M | -22.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $696.15M | +331.3% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $161.41M | +48.8% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $108.50M | +4.1% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $104.27M | +525.9% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $16.66M | -76.1% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $69.59M | n/a | 2021-03-02, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $383.75M | -29.3% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare RVMD, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗